Charles McWherter, President of R&D at CymaBay Therapeutics, Inc. (CBAY), sold 31,765 shares at $23.68 ($752K) on 2024-01-19, disclosed to the SEC on 2024-01-22.
Scheduled sale ($752k) by President of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.66 | 1,916 | $45K | 6.0% |
| 2 | $23.66 | 2,778 | $66K | 8.7% |
| 3 | $23.66 | 2,778 | $66K | 8.7% |
| 4 | $23.67 | 2,250 | $53K | 7.1% |
| 5 | $23.67 | 2,250 | $53K | 7.1% |
| 6 | $23.68 | 8,334 |
| $197K |
| 26.2% |
| 7 | $23.68 | 8,334 | $197K | 26.2% |
| 8 | $23.68 | 3,125 | $74K | 9.8% |
| Total | $23.67 avg | 31,765 | $752K | 100% |
| Filing → |
| CBAY | SELL | 2023-12-18 | $487K | — | Filing → |
| CBAY | SELL | 2023-11-17 | $415K | — | Filing → |
| CBAY | SELL | 2023-10-18 | $612K | — | Filing → |